martes, 21 de julio de 2020

Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand | BMC Cancer | Full Text

Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand | BMC Cancer | Full Text

Targeted treatment with Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) is superior to systemic chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR gene mutations. Dete...
Authors:Phyu Sin Aye, Sandar Tin Tin, Mark James McKeage, Prashannata Khwaounjoo, Alana Cavadino and J. Mark Elwood
Citation:BMC Cancer 2020 20:658
Content type:Research article
 
Published on: 

No hay comentarios:

Publicar un comentario